Literature DB >> 17210721

RET/papillary thyroid carcinoma oncogenic signaling through the Rap1 small GTPase.

Valentina De Falco1, Maria Domenica Castellone, Gabriella De Vita, Anna Maria Cirafici, Jerome M Hershman, Carmen Guerrero, Alfredo Fusco, Rosa Marina Melillo, Massimo Santoro.   

Abstract

RET/papillary thyroid carcinoma (PTC) oncoproteins result from the in-frame fusion of the RET receptor tyrosine kinase with protein dimerization motifs encoded by heterologous genes. Here, we show that RET/PTC1 activates the Rap1 small GTPase. The activation of Rap1 was dependent on the phosphorylation of RET Tyr(1062). RET/PTC1 recruited a complex containing growth factor receptor binding protein 2-associated binding protein 1 (Gab1), CrkII (v-crk sarcoma virus CT10 oncogene homologue II), and C3G (Rap guanine nucleotide exchange factor 1). By using dominant-negative and small interfering duplex (small interfering RNA) oligonucleotides, we show that RET/PTC1-mediated Rap1 activation was dependent on CrkII, C3G, and Gab1. Activation of Rap1 was involved in the RET/PTC1-mediated stimulation of the BRAF kinase and the p42/p44 mitogen-activated protein kinases. Proliferation and stress fiber formation of RET/PTC1-expressing PC Cl 3 thyroid follicular cells were inhibited by the dominant-negative Rap1(N17) and by Rap1-specific GTPase-activating protein. Thus, Rap1 is a downstream effector of RET/PTC and may contribute to the transformed phenotype of RET/PTC-expressing thyrocytes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17210721     DOI: 10.1158/0008-5472.CAN-06-0981

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  19 in total

1.  siRNA as a tool for investigating organogenesis: The pitfalls and the promises.

Authors:  Wen-Chin Lee; Rachel Berry; Peter Hohenstein; Jamie Davies
Journal:  Organogenesis       Date:  2008-07       Impact factor: 2.500

2.  Histone deacetylase inhibitors upregulate Rap1GAP and inhibit Rap activity in thyroid tumor cells.

Authors:  Xiaoyun Dong; Christopher Korch; Judy L Meinkoth
Journal:  Endocr Relat Cancer       Date:  2011-04-02       Impact factor: 5.678

3.  Identification of functionally distinct TRAF proinflammatory and phosphatidylinositol 3-kinase/mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (PI3K/MEK) transforming activities emanating from RET/PTC fusion oncoprotein.

Authors:  Josephine H F Wixted; Jay L Rothstein; Laurence C Eisenlohr
Journal:  J Biol Chem       Date:  2011-12-09       Impact factor: 5.157

4.  Epigenetic modifications in human thyroid cancer.

Authors:  Bita Faam; Mohammad Ali Ghaffari; Ata Ghadiri; Fereidoun Azizi
Journal:  Biomed Rep       Date:  2014-11-03

5.  Downregulation of Rap1GAP through epigenetic silencing and loss of heterozygosity promotes invasion and progression of thyroid tumors.

Authors:  Hui Zuo; Manoj Gandhi; Martin M Edreira; Daniel Hochbaum; Vishwajit L Nimgaonkar; Ping Zhang; James Dipaola; Viktoria Evdokimova; Daniel L Altschuler; Yuri E Nikiforov
Journal:  Cancer Res       Date:  2010-02-02       Impact factor: 12.701

Review 6.  EPAC proteins transduce diverse cellular actions of cAMP.

Authors:  Gillian Borland; Brian O Smith; Stephen J Yarwood
Journal:  Br J Pharmacol       Date:  2009-02-06       Impact factor: 8.739

Review 7.  Insights into exchange factor directly activated by cAMP (EPAC) as potential target for cancer treatment.

Authors:  Naveen Kumar; Peeyush Prasad; Eshna Jash; Megha Saini; Amjad Husain; Aaron Goldman; Seema Sehrawat
Journal:  Mol Cell Biochem       Date:  2018-02-07       Impact factor: 3.396

8.  Crk and CrkL adaptor proteins: networks for physiological and pathological signaling.

Authors:  Raymond B Birge; Charalampos Kalodimos; Fuyuhiko Inagaki; Shinya Tanaka
Journal:  Cell Commun Signal       Date:  2009-05-10       Impact factor: 5.712

9.  Computational modelling of cancerous mutations in the EGFR/ERK signalling pathway.

Authors:  Richard J Orton; Michiel E Adriaens; Amelie Gormand; Oliver E Sturm; Walter Kolch; David R Gilbert
Journal:  BMC Syst Biol       Date:  2009-10-05

10.  Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers.

Authors:  Hihu Wing Cheung; Jinyan Du; Jesse S Boehm; Frank He; Barbara A Weir; Xiaoxing Wang; Mohit Butaney; Lecia V Sequist; Biao Luo; Jeffrey A Engelman; David E Root; Matthew Meyerson; Todd R Golub; Pasi A Jänne; William C Hahn
Journal:  Cancer Discov       Date:  2011-10-17       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.